

Screening for Analgesic and Anti-Inflammatory Effect of Antioxidants by Applying Formalin Test Using Albino Mice

Aburawi S*, Al Tubuly R, Friwan A, Al-Ghdamsi M

Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, University of Tripoli, Libya

Email: smaburawi@gmail.com

Received: 26,06,2017

Accepted: 08,07,2017

ABSTRACT

Objective: Aim of this work is to evaluate analgesic and anti-inflammatory effects of antioxidants. **Methods:** Formalin test was applied using albino mice. This model constitutes two distinct phases: the first phase represents the irritating effect of formalin at the sensorial fiber-C, while the second phase is inflammatory pain response. **Results:** Vitamin C, vitamin E and selenium have analgesic effect for neuropathic pain. Vitamin E and selenium produce anti-inflammatory effect. **Conclusion:** Analgesic effect for neuropathic pain was observed with vitamin C, vitamin E and selenium treatment. Anti-inflammatory effect is produced by vitamin E and selenium administration; while Vitamin C produces insignificant decrease in inflammation in the dose used.

Keywords: Antioxidant, Vitamin C, Vitamin E, Selenium, Formalin Test.

INTRODUCTION

Antioxidants, such as vitamin C, vitamin E and selenium, are a reducing agent, protect the body from the oxidation reaction that induced by free radicals [1]. They have important roles in the biochemistry of living organisms [2,3]. Antioxidants are either water soluble (hydrophilic) as vitamin C or lipids soluble (hydrophobic) as vitamin E [4]; hydrophilic antioxidant protect cell cytosol and blood plasma from oxidation, while hydrophobic antioxidant protect cell membrane from lipid peroxidation. These antioxidants may be synthesized in the body or obtain as nutrition [5].

Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are normally generated either from mitochondrial electron-transport chain or excessive stimulation of NADPH leading to oxidative stress, that damage cell structure including lipid, membrane, protein, and DNA [6].

Vitamin C (L-ascorbic acid) is safe and effective antioxidant nutrient. It is needed by the body to make collagen. Vitamin C is used as therapy for scurvy, increase the absorption of iron, and enhance immune function [7]. Vitamin C is used to prevent and treat cold, infection, bronchitis, human immunodeficiency (HIV) disease, stomach ulcer caused by bacteria *Helicobacter pylori*, tuberculosis, dysentery, and skin infection. Also, it may be used for depression, thinking problems, dementia, physical and mental stress, fatigue and attention deficit-hyperactivity disorder (ADHD) [8].

Vitamin E as a fat-soluble antioxidant, protect cell damage induced by free radical [9]. Vitamin E has a role in immune function, cells - cell signaling, regulation of gene expression and other metabolic processes [10].

Selenium as mineral antioxidant, plays key role in metabolism and protect cell from damage [11]. The aim of this study is to screen for analgesic and anti-inflammatory effect of antioxidants.

Antioxidant used were water soluble vitamin (vitamin C), fat soluble vitamin (vitamin E) and mineral as selenium. Formalin test was applied in this study.

Cite this article: Aburawi S, Al Tubuly R, Friwan A, Al-Ghdamsi M. Screening for analgesic and anti-inflammatory effect of antioxidants by applying formalin test using albino mice. *Alq. J. Med. Bio Res*, 2017;1(1):1-

METHODOLOGY

Materials

Tween 80 was purchased from 250mg/kg. Vitamin C was obtained from pharmaceutical chemical company, Elnaser – Egypt. Vitamin E was obtained from Genesisuit company, Doral, Florida, USA. Selenium was obtained from Jamieson company, Toronto - Canada. Tramadol was purchased from Medis BP company, Nabeul - Tunisie, while lysine acetylsalicylate from Amiriya company, Alexandria - Egypt. Formalin was purchased from Al Hashan pharmacy Ain zara-Tripoli- Libya.

Animals

Male albino wister mice weighing between (25-40gm) were housed at constant room temperature (20-25°C) under 12h light/12 dark cycle and with access to food and water with standard mice food pellet diet; water was available *ad libitum*. Mice were housed in the Faculty of Pharmacy, Tripoli University. Each group of mice was housed separately in a cage during the time of experiment.

Methods

Mice were randomly assigned to receive different treatments or vehicle. Tween 80 (1%) was used as suspending agent for all drugs and as a control (Rogoz et al., 2005). A volume of injection of 5ml/kg of body weight was adopted for all experiments (Swayeh et al., 2000).

Mice were divided randomly into six groups of (n=8) animals. Group 1, control group, administered 1% Tween 80, group 2, administered vitamin C (250mg/kg), group 3, administered vitamin E (400UI/kg), group 4, administered selenium (50µg/kg), group 5, administered tramadol (5mg/kg), group 6, administered acetyl salicylic acid (200mg/kg).

Different concentration of drugs was freshly prepared prior to use. Subacute administration was applied, where the drugs injected (i.p.) three doses (24, 5, 1 hour) before injecting formalin and scoring.

Acetyl salicylic acid is used as standard (Guimarães et al., 2009) for formalin test phase II (anti-inflammatory), and tramadol as standard drug for formalin test phase I (analgesic) (Rajani et al, 2009).

Screening of analgesic and anti-inflammatory effect of antioxidants were carried out using formalin test.

Formalin-Induced Nociception

Formalin 3% was injected subcutaneously into the surface of the right hind paw using a 30-gauge needle. The animals were then placed in a clear Plexiglas cylinder (20_30 cm) for observation. The pain behaviour was quantified by determining the duration of time (s) the mouse spent licking the injected paw (Abbot et al, 1995).

Two phases of spontaneous licking behaviour were observed after the formalin injection. The interval from 0 to 5 min has been defined as Phase I (neuropathic pain phase), and the interval from 15 to 30 min has been defined as Phase II (inflammatory pain phase) (Abbot et al, 1995; Guimarães et al., 2009).

Statistical analysis

Descriptive statistical analysis was performed using computer program SPSS (version 13) to verify whether the data were parametric by using Kolmogrove-Simirnov test maximum deviation test for goodness of fit. If the parameters were parametric, treatments were compared by one-way ANOVA, Post-Hoc test (LSD and Duncan test) was applied. If the parameters were non-parametric, treatments were compared by Mann-Whitney U test. The differences were considered significant at P value ≤ 0.05 . The values are expressed as mean \pm standard error.

RESULTS

Screening of analgesic effect using formalin test (phase I)

During phase I (analgesic effect for neuropathic pain), Vitamin C, vitamin E, selenium, tramadol, and acetyl salicylic acid showed an increase in the duration of licking at $p=0.006$, $p=0.000$, $p=0.000$, $p=0.000$, $p=0.000$ respectively compared to the control (table 1).

Table 1: Screening for analgesic effect of antioxidants applying formalin test (Phase I)

Treatment (n=8)	Duration of licking (Phase I)
1% T80 (control)	113.8 \pm 10.64
Vitamin C (250 mg/kg)	78.1 \pm 4.63 *

Vitamin E (400 IU/kg)	66.6 ± 10.33 *
Selenium (50 µg/kg)	58.6 ± 12.34 *
Tramadol (5 mg/kg)	55.3 ± 1.87 *
acetyl salicylic acid (200 mg/kg)	63.6 ± 7.35 *

* Significantly different from control at $p \leq 0.05$.

Screening of anti-inflammatory effect using formalin test (phase II)

During phase II (anti-inflammatory phase), Vitamin C produce insignificant decrease in the duration of licking ($p=0.059$); while vitamin E, selenium, tramadol, and acetyl salicylic acid showed an increase in the duration of licking at $p=0.000$, $p=0.000$, $p=0.000$, $p=0.000$ respectively compared to the control (table 2).

Table 2: Screening for anti-inflammatory effect of Antioxidants applying formalin test (Phase II)

Treatment (n=8)	Duration of licking (Phase II)
1% T80 (control)	214.3 ± 60.02
Vitamin C (250 mg/kg)	139.5 ± 23.41
Vitamin E (400 IU/kg)	35.6 ± 8.59 *, a
Selenium (50 µg/kg)	39.1 ± 9.71 *, a
Tramadol (5 mg/kg)	44.5 ± 9.06 *, a
acetyl salicylic acid (200 mg/kg)	60.1 ± 7.84 *, a

*, Significantly different from control at $p \leq 0.05$; a, Significantly different from vitamin C at $p \leq 0.05$

DISCUSSION

Oxidative stress is an important mediator of damage to cell structure including lipid, membrane, protein, and DNA [6]. The body forms ROS endogenously, when it converts food to energy, while antioxidant protect cells from damaging effect of ROS [9].

Reactive oxygen species (ROS) contributes to the development of exaggerated pain hypersensitivity during persistent pain [12]. Formalin test is one of the most used models to explain pain and analgesia mechanisms, with better results than tests using mechanical or thermal stimulus [13]. This model constitutes two distinct phases: the first phase represents the irritating effect of formalin at the sensorial fiber-C, while the second phase is an inflammatory pain response.

Vitamin C exerted its antinociceptive effects primarily because of its antioxidant properties; it has a major role in reducing pain in many clinical conditions [14]. Dopamine receptors agonists facilitate analgesic responses [15,16]. Antinociceptive action of vitamin C was reduced by metoclopramide (dopamine antagonist) [17]. Dopaminergic system involved in the mechanisms of antinociception of vitamin C [18].

Spinal analgesic actions are modulated through 5-HT released from brainstem structures [19-21]. Vitamin C analgesic effect was inhibited by ondansetron, a serotonin antagonist [22]; therefor vitamin C may modulate its analgesic effect through 5HT release.

NMDA receptor, which is essentially contributes to nociceptive processing during both inflammatory and neuropathic pain, is redox regulated [23]; its activity can be inhibited by Vitamin C administration [24]. Therefore, Vitamin C may produce its antinociception by interaction with ionotropic glutamate receptors [12,24].

Three major members of MAPK family (Mitogen-Activated Protein kinase, p38, ERK and JNK) play a major role in the maintenance of persistent pain [25]. Peripheral nerve injury leads to activation of p38, ERK and JNK in glial cells, leading to the synthesis of proinflammatory/pronociceptive mediators, enhancing and prolonging neuropathic pain. Vitamin C treatment reduces p38 but not ERK (p42/p44) phosphorylation in the spinal cord and dorsal root ganglia; this indicates that vitamin C inhibits p38-dependent nociceptive signaling in spinal cord microglia and dorsal root ganglia neurons [26].

Vitamin E produces analgesic effect in phase I. Analgesic effects of vitamin E may be partially explained through its antioxidant properties, involve blocking the production of reactive oxygen species (ROS) that are involved in neuropathic pain. Vitamin E produces analgesia in neuropathic pain that is, mediated by reducing central sensitization [27]; it has the ability to

make the brain less sensitive to pain.

Alpha-tocopherol produces pain relief in patients with algomenorrhea through endogenous opioid system. There was an increase in beta-endorphin after alpha-tocopherol administration and naloxone administration resumed the pain [28].

Vitamin E treatment reduces p38 but not ERK (p42/p44) phosphorylation in the spinal cord and dorsal root ganglia, leading to inhibition of p38-dependent nociceptive signaling [26].

Tramadol produces analgesic effect in phase I. Tramadol hydrochloride is an orally active, centrally acting analgesic [29,30]; it possesses opioid agonist activity and activates the spinal pain inhibitory system [31]. Tramadol produce its action through binding to μ -opioid receptor [32,33].

Tramadol provide pain relief by blockade of serotonin action [34-36], through 5-HT1A auto receptors from raphe nuclei [37]; also, tramadol inhibits the reuptake of serotonin and norepinephrine [32,33].

Selenium produces analgesic effect in phase I, it may produce its effect through increasing the analgesic activity of opioids, as observed using vincristine model of chemotherapeutic-induced painful toxic neuropathy; this model resulted in progressive decrease of pain threshold [38].

Selenium, as an antioxidant, has protective effects on cytosolic Ca²⁺ release in cell lines; it decreases calcium ion influx and oxidative stress through voltage gated and melastatin-like transient receptor potential 2 (TRPM2) cation channels [40].

Selenium protect from H₂O₂ that increase Ca²⁺ influx and oxidative stress through regulation of TRPM2 channels. It was found that, selenium inhibits completely H₂O₂-induced TRPM2 activation; also, decrease cytosolic Ca²⁺ release and lipid peroxidation levels [40].

TRPM2 channels involved in nociceptive processing [41,42] and the production of chemokine in inflammation [43]. Therefore, blocking nociception-related TRPM2 channels by selenium will produce analgesic effect [42].

Acetylsalicylic acid produces analgesic effect in phase I, it has antinociceptive activity in formalin test. It significantly increased brain serotonin (5-HT) content and reduced the number of 5-HT₂ receptors in cortical brain membranes. It was suggested also that acetylsalicylic acid may exert its antinociceptive action through opiate pathways as antinociceptive activity of acetylsalicylic acid is abolished by naloxone [44].

Vitamin C produces insignificant anti-inflammatory effect (phase II); from previous work, free radicals have pro-inflammatory effects [45]; also in clinical trial, vitamin C supplementation for two months resulted in a decrease the level of C-reactive protein (CRP, inflammatory marker) in those with elevated CRP levels [46]; but no effect of vitamin C supplement in those with baseline levels of CRP. Vitamin C significantly reduce pro-inflammatory cytokines (cytokines IL-1 α , IL-2, IL-8, TNF- α , chemokine, eotaxin and C-reactive protein) [47]. From previous research, it was found that vitamin C has anti-inflammatory effect; in this study, Vitamin C produces insignificant reduction in inflammation, this may due to vitamin C dose should be increased to have a significant reduction in inflammation.

Vitamin E produces anti-inflammatory effect (phase II), this may due to its antioxidant functions [48]. Vitamin E has anti-inflammatory effect by inhibiting the release of arachidonic acid and the conversion of arachidonic acid to prostaglandin (PGE₂) via an action on phospholipase A₂ and cyclooxygenase enzymes [49,50].

Alpha-tocopherol exerts its anti-inflammatory effects through a decrease in the levels and inhibits the activity of protein kinase C; also by decreases the level of pro-inflammatory cytokines and inhibits cyclooxygenase-2 [48,52].

Complement-neutrophil-reactive oxygen activation feedback (CNAF) mechanism mediated inflammatory response; it was found that, vitamin E inhibits CNAF mechanism [52]. Vitamin E have been shown to decrease inflammatory prostaglandin synthesis, interleukin production, and the induction of cyclooxygenase-2 (COX-2) and NADPH oxidase by UV light exposed skin [53-55].

Selenium produces anti-inflammatory effect (phase II), complement-neutrophil-reactive oxygen activation feedback (CNAF) mechanism mediated inflammatory response was inhibited by sodium selenite [52]. Selenium suppresses the redox-sensitive transcription factor NF-kappa B-dependent pro-inflammatory gene expression. Selenium increases the production of 15d-PGJ₂ as an adaptive response to protect cells against oxidative stress-induced pro-inflammatory gene expression [56].

Selenium plays an important role as an anti-inflammatory agent by tightly regulating the expression of pro-inflammatory genes in immune cells. Selenium anti-inflammatory effect is through a decrease in Lipopolysaccharides-induced expression of two

important pro-inflammatory genes, cyclooxygenase-2 (COX-2) and tumor necrosis factor-alpha (TNF-alpha) and via the inhibition of Mitogen-activated protein kinases (MAPK) pathways^[57]; where MAPK stimulates proinflammatory cytokines, while Lipopolysaccharides (LPS) is bacterial endotoxin.

Tramadol produces anti-inflammatory effect (phase II), this may be through reducing prostaglandin E2 concentrations in inflammatory exudates^[578,59]. Also through serotonergic and noradrenergic transmission, it may reduce inflammatory edema; tramadol inhibits noradrenaline and serotonin reuptake, leading to analgesic action by blocking nociceptive impulses at the spinal level^[60,61]. Tramadol may inhibit inflammatory mediators such as IL-6 in patients and reduce the release of substance p, as observed with knee osteoarthritis^[62].

Acetylsalicylic acid produces anti-inflammatory effect (phase II), it inhibited the production of prostaglandins via an inhibitory effect on cyclooxygenase (COX) enzymes; this may account for its anti-inflammatory action^[63-65].

Salicylic acid modulates signaling through nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), which responsible for cytokine production; it is a transcription factor complex that plays a central role in many biological processes, including inflammation^[66].

CONCLUSION

Vitamin C, vitamin E and selenium have analgesic effect for neuropathic pain. Vitamin E and selenium produce anti-inflammatory effect; while Vitamin C produces insignificant decrease in inflammation in the dose used. Vitamin C may show anti-inflammatory effect with increasing the dose.

DISCLOSURE STATEMENT

Conflict of interest statement was not declared.

REFERENCES

1. Harman, D. (1982). Nutritional implication of the free radical theory of aging. *J Am Coll Nutr.*; 1:27-34.
2. Jacob, R.A. (1996). "Three eras of vitamin C discovery". *Sub-Cellular Biochemistry. Subcellular Biochemistry* 25: 1–16. doi:10.1007/978-1-4613-0325-1_1. ISBN 978-1-4613-7998-0. PMID 8821966.
3. Knight, J.A. (1998). "Free radicals: their history and current status in aging and disease". *Annals of Clinical and Laboratory Science* 28 (6): 331–46. PMID 9846200.
4. Sies, H. (1997). "Oxidative stress: oxidants and antioxidants". *Experimental Physiology*; 82(2):291–295. doi:10.1113/expphysiol.1997.sp004024. PMID 9129943.
5. Vertuani, S., A. Angusti, and S. Manfredini (2004). "The antioxidants and pro-antioxidants network: an overview". *Current Pharmaceutical Design*; 10(14): 1677–1694. doi:10.2174/1381612043384655. PMID 15134565.
6. Valko, M., M. Izakovic, M. Mazur, C.J. Rhodes, and J. Telser (2004). Role of oxygen radical in DNA damage and cancer incidence. *Mol. cell. Biochem.*; 266(1-2): 37-56.
7. Padayatty, S.J., A. Katz, Y. Wang, P. Eck, O. Kwon, J.H. Lee, S. Chen, and S. K. Dutta (2003). *Pub Med (Am coll Nutr 2003) Vitamin C as an antioxidant evaluation of its role in disease prevention.* www.ncbi.nih.gov/pubmed/12569111
8. Higdon, J., Ph.D, 2000 Micronutrient information Center Reviewed in November, 2013 by Alexander J .Mchels, Ph.D.Research Associate,linus pauling Oregon State University. lpi.oregonstate.edu/mic/vitamin C.
9. Bjelakovic, G., D. Nikolova, L.L. Gluud, et al. (2012); Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. *Cochrane.* 3:CD007176.
10. Traber, M.G., "Vitamin E" in; Shils M.E., M. Shike, A.C. Ross, B. Caballero, and R.J. Cousins (2006). *Modern Nutrition in Health and Disease*, 10th ed. Philadelphia: Lippincott Williams & Wilkins; 396-411.
11. Rayman, M.P. (2000). The importance of selenium to human health *lancet* 356(9225): 233-41.
12. Lu, R., W. Kallenborn-Gerhardt, G. Geisslinger, A. Schmidtko (2011). Additive Antinociceptive Effects of a Combination of Vitamin C and Vitamin E after Peripheral Nerve Injury. *PLoS ONE* 6(12): e29240. doi:10.1371/journal.pone.0029240.

13. Tjølsen, A., O.G. Berge, S. Hunnskaar, J.H. Rosland, and K. Hole (1992). Review: The formalin test: an evaluation of the method. *Pain*; 51(1):5–17. doi: 10.1016/0304-3959(92)90003-T.
14. Kapoor, S. (2012). Vitamin C and its emerging role in pain management: beneficial effects in pain conditions besides post herpetic neu-ralgia. *Korean J Pain*; 25(3):200–1.
15. Michael-Titus, A., and R. Bousselmame (1990). Costentin J. Stimulation of dopamine D2 receptors induces an analgesia involving an opiodergic but non enkephalinergic link. *Eur J Pharmacol.* 187(2):201–7.
16. Suaudeau, C., and J. Costentin (1995). Analgesic effect of the direct D2 dopamine receptor agonist RU 24926 and cross tolerance with morphine. *Fundam Clin. Pharmacol.*; 9(2):147–52.
17. Zeraati, F., M. Araghchian, and M.H. Farjoo (2014). Ascorbic Acid Interaction With Analgesic Effect of Morphine and Tramadol in Mice. *Anesth. Pain Med.*; 4(3): e19529.
18. Onozawa, K., Y. Yagasaki, Y. Izawa, H. Abe, and Y. Kawakami (2011). Amygdala prefrontal pathways and the dopamine system affect nociceptive responses in the prefrontal cortex. *BMC Neurosci.* 12:115.
19. Yaksh, T.L., and G.M. Tyce (1979). Microinjection of morphine into the periaqueductal gray evokes the release of serotonin from spinal cord. *Brain Res.*; 171(1):176–81.
20. Yaksh, T.L., and P.R. Wilson (1979). Spinal serotonin terminal system mediates antinociception. *J Pharmacol Exp Ther.* 208(3):446–53.
21. Zeitz, K.P., N. Guy, A.B. Malmberg, S. Dirajlal, W.J. Martin, L. Sun, et al. (2002). The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. *J Neurosci.* 22(3):1010–9.
22. Zeraati, F., M. Araghchian, and M.H. Farjoo (2014). Ascorbic Acid Interaction With Analgesic Effect of Morphine and Tramadol in Mice. *Anesth. Pain Med.*; 4(3): e19529.
23. Waring, P. (2005) Redox active calcium ion channels and cell death. *Arch Biochem Biophys.*; 434: 33–42.
24. Rosa, K.A., V.M. Gadotti, A.O. Rosa, A.L. Rodrigues, J.B. Calixto, and A.R. Santos (2005). Evidence for the involvement of glutamatergic system in the antinociceptive effect of ascorbic acid. *Neurosci. Lett.* 381(1-2):185–8.
25. Ji, R.R., R.W. Gereau., M. Malcangio, and G.R. Strichartz (2009) MAP kinase and pain. *Brain Res Rev.*; 60: 135–148. doi: 10.1016/j.brainresrev.2008.12.011.
26. Clerk, A., S.J. Fuller, A. Michael, and P.H. Sugden (1998) Stimulation of “stress regulated” mitogen-activated protein kinases (stress-activated protein kinases/c-Jun N-terminal kinases and p38-mitogen-activated protein kinases) in perfused rat hearts by oxidative and other stresses. *J Biol Chem.*; 273: 7228–7234.
27. Kim, H.K., J.H. Kim, X. Gao, J.L. Zhou, I. Lee, K. Chung, and J.M. Chung (2006). Analgesic effect of vitamin E is mediated by reducing central sensitization in neuropathic pain. *Pain.* 122(1-2): 53–62.
28. Kryzhanovskii, G.N., L.P. Bakuleva, N.L. Luzina, V.A. Vinogradov, and K.N. Iarygin (1988). Endogenous opioid system in the realization of the analgesic effect of alpha-tocopherol in reference to algomenorrhea. *Biulleten' eksperimental'noi biologii i meditsiny* ; 105(2):148-150.
29. Lee, C.R., D. McTavish, and E.M. Sorkin (1993). Tramadol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. *Drugs*; 46:313-40.
30. Angeletti, C., C. Guetti, A. Paladini, and G. Varrassi (2013). Review: Tramadol Extended-Release for the Management of Pain due to Osteoarthritis. Hindawi Publishing Corporation ISRN Pain Volume 2013, Article ID 245346, 16 pages <http://dx.doi.org/10.1155/2013/245346>
31. Husslein, P., E. Kubista, and C. Egarter (1987). Obstetric Analgesia with Tramadol – Results of a prospective randomised comparison with pethidine. *Zeitschrift für Geburtshilfe und perinatology*; 191, 234–237
32. Leppert, W. (2009). "Tramadol as an analgesic for mild to moderate cancer pain.". *Pharmacological reports* 61 (6): 978–92. doi:10.1016/s1734-1140(09)70159-8.
33. Awad, N. (2015). Now What? DEA Tosses Tramadol in Schedule IV. Reviewed by Zalman S. Agus, MD. last updated 01.14.2015
34. Grond, S., and A. Sablotzki (2004). Clinical pharmacology of tramadol. *Clin Pharmacokinet.*; 43: 879–923.

35. Berrocoso, E., M.D. De Benito, and J.A. Mico (2007). Role of serotonin 5HT1A and opioid receptors in the antiallodynic effect of tramadol in the chronic constriction injury model of neuropathic pain in rats. *Psychopharmacology (Berl)* 193:97–105.
36. Xie, H., Z.Q. Dong, F. Ma, W.R. Bauer, X. Wang, and G.C. Wu (2008). Involvement of serotonin 2A receptors in the analgesic effect of tramadol in monoarthritic rats. *Brain Res.*; 1210: 76–83.
37. Berrocoso, E., M.O. Rojas-Corrales, and J.A. Mico (2006). Differential role of 5-HT1A and 5-HT1B receptors on the antinociceptive and antidepressant effect of tramadol in mice. *Psychopharmacology*. 188(1):111.
38. Bujalska, M.I., and S.W. Gumułka (2009). Effect of selol on the opioids activity in vincristine induced hyperalgesia. *Akademia Medyczna, Żwirki i Wigury* 61, Warszawa 02-091, Poland.
39. Nazıroğlu, M., C. Özgül, M. Küçükayaz, B. Çiğ, S. Hebeisen, and R. Bal (2012) Selenium attenuates calcium ion influx and oxidative stress through voltage gated and TRPM2 cation channels in transfected cells. 4th International Congress on Cell Membranes and Oxidative Stress: Focus on Calcium Signaling and TRP Channels. Poster, Volume 4, Number 1, 26.
40. Nazıroğlu, M., C. Özgül, M. Küçükayaz, B. Çiğ, S. Hebeisen, and R. Bal (2012) Selenium attenuates calcium ion influx and oxidative stress through voltage gated and TRPM2 cation channels in transfected cells. 4th International Congress on Cell Membranes and Oxidative Stress: Focus on Calcium Signaling and TRP Channels. Poster, Volume 4, Number 1, 26.
41. Haraguchi, K., A. Kawamoto, K. Isami, S. Maeda, A. Kusano, K. Asakura et al. (2012). TRPM2 contributes to inflammatory and neuropathic pain through the aggravation of pronociceptive inflammatory responses in mice. *J Neurosci.*; 32: 3931–3941.
42. Sousa-Valente, J., A.P. Andreou, L. Urban, I. Nagy (2014). Review: Transient receptor potential ion channels in primary sensory neurons as targets for novel analgesics. *British Journal of Pharmacology*; 171: 2508–2527. DOI:10.1111/bph.12532.
43. Zholos, A. (2010). Pharmacology of transient receptor potential melastatin channels in the vasculature. *Br J Pharmacol.*; 159(8): 1559–1571. doi: 10.1111/j.14765381.2010.00649.
44. Pini, L.A., G. Vitale, and M. Sandrini (1997). Serotonin and Opiate Involvement in the Antinociceptive Effect of Acetylsalicylic Acid. *Pharmacology*; 54:84–91. (DOI:10.1159/000139473)
45. Seaman, D.R. (2002). The diet-induced proinflammatory state: a cause of chronic pain and other degenerative diseases? *J Manipulative Physiol Ther.*; 25(3): 168-79.
46. Block, G., C.D. Jensen, T.B. Dalvi, et al. (2009). Vitamin C treatment reduces elevated C-reactive protein. *Free Radic Biol Med.*; 46(1): 70-77.
47. Mikirova, N., J. Casciari, A. Rogers, and P. Taylor (2012). Effect of high-dose intravenous vitamin C on inflammation in cancer patients. *Journal of Translational Medicine*, 10:189. <http://www.translational-medicine.com/content/10/1/18>
48. Calder, P.C., R. Albers, J.M. Antoine, et al. (2009). Inflammatory disease processes and interactions with nutrition. *Br J Nutr*; 101 Suppl 1: S1-45.
49. Ellattar, T.M.A., and H.S. Lin (1992). Effect of vitamin C and vitamin E on prostaglandin synthesis by fibroblasts and squamous carcinoma cells. *Prostaglandins Leukot Essent Fat Acids*; 47:253–257.
50. Wu, D., C. Mura, A.A. Beharka, S.N. Han, K. E. Paulson, D. Hwang, and S.N. Meydani. (1998). Age-associated increase in PGE2 synthesis and COX activity in murine macrophages is reversed by vitamin E. *Am. J. Physiol.* 275 (Cell Physiol. 44): C661–C668.
51. Singh, U., S. Devaraj, and I. Jialal (2005). Vitamin E, oxidative stress, and inflammation. *Annu Rev Nutr.*; 25: 151-74.
52. Hou, J., Y. Wu, and Y. Ling (2000). Modulation of the inflammatory response through complement neutrophil activation feedback mechanism with selenium and vitamin E. *Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae*; 22(6):580-4. <http://science.naturalnews.com/pubmed/12903410.html>
53. Wu, S., J. Gao, Q.T. Dinh, C. Chen, and S. Fimmel (2008). IL-8 production and AP-1 transactivation

- induced by UVA in human keratinocytes: roles of D-alpha-tocopherol. *Mol Immunol.*; 45(8):2288-2296.
54. Shibata, A., K. Nakagawa, Y. Kawakami, T. Tsuzuki, and T. Miyazawa (2010). Suppression of gamma-tocotrienol on UVB induced inflammation in HaCaT keratinocytes and HR-1 hairless mice via inflammatory mediators multiple signaling. *J Agric Food Chem.*; 58(11): 7013-7020.
55. Kato, E., Y. Sasaki, and N. Takahashi (2011) Sodium dl-alpha-tocopheryl-6-O-phosphate inhibits PGE(2) production in keratinocytes induced by UVB, IL-1beta and peroxidants. *Bioorg Med Chem.*;19(21):6348-6355.
56. Vunta, H., F. Davis, U.D. Palempalli, D. Bhat, R.J. Arner, J.T. Thompson, D.G. Peterson, C.C. Reddy, and K.S. Prabhu (2007). The anti-inflammatory effects of selenium are mediated through 15 deoxy Delta12,14 prostaglandin J2 in macrophages. *J Biol Chem.*; 282(25):17964-17973. Doi:10.1074/jbc.M703075200
57. Vunta, H., F. Davis, U.D. Palempalli, D. Bhat, R.J. Arner, J.T. Thompson, D.G. Peterson, C.C. Reddy, and K.S. Prabhu (2007). The anti-inflammatory effects of selenium are mediated through 15 deoxy Delta12,14 prostaglandin J2 in macrophages. *J Biol Chem.*; 282(25):17964-17973. Doi:10.1074/jbc.M703075200
58. Bianchi, M., G. Rossoni, P. Sacerdote, and A.E. Panerai (1999). Effects of tramadol on experimental inflammation. *Fundam. Clin. Pharmacol.*; 13:220–225.
59. Buccellati, C., A. Sala, R. Ballerio, and M. Bianchi (2000). Tramadol anti-inflammatory activity is not related to a direct inhibitory action on prostaglandin endoperoxide synthases. *Eur J Pain*; 4(4):413-415.
60. Dayer, P., J. Desmeules, L. Collart (1997). Pharmacology of tramadol. *Drugs*; 53(suppl 2):18–24.
61. Sacerdote, P., M. Bianchi, B. Manfredi, and A.E. Panerai (1997). Effects of tramadol on immune responses and nociceptive thresholds in mice. *Pain*; 72:325-330.
62. Bianchi, M., M. Brogini, P. Balzarini, E. Baratelli, P. Ferrario, A.E. Panerai, and P. Sacerdote (2003). Effects of tramadol on synovial fluid concentrations of substance P and interleukin-6 in patients with knee osteoarthritis: comparison with paracetamol. *Int. Immunopharmacol.*; 3:1901-1908. DOI: 10.1016/j.intimp.2003.08.011.
63. Vane, J.R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. *Nature New Biol.* 231:232-235.
64. Roth, G.J., N. Stanford, and P.W. Majerus (1975). Acetylation of prostaglandin synthase by aspirin. *Proc Natl Acad Sci USA*; 72:3073-3076.
65. Willis, A.L., and D.L. Smith (1997). Metabolism of arachidonic acid. In: Cunningham FM, ed. *The Handbook of Immunopharmacology and Lipid Mediators*. London: Academic Press; 1994: 1-32.
66. McCarty, M.F., and K.I. Block (2006). "Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy.". *Integr Cancer Ther.*; 5 (3): 252–268.